10月8日 - ** 药物开发商Werewolf Therapeutics HOWL.O的股价盘前上涨20%至2.32美元
** 该公司称其实验性癌症疗法WTX-124获得了美国食品及药物管理局（FDA）的 "快速通道 (link)"认证。
** 该疗法旨在治疗已经接受过标准免疫疗法的晚期皮肤癌患者
** 美国食品及药物管理局的 "快速通道 "标签旨在加快开发和审查用于治疗未满足医疗需求的严重疾病的药物
** WTX-124正在一项早期试验中进行测试，既可作为独立疗法，也可与默克公司的MRK.N Keytruda联合使用。
** 截至上一交易日收盘，股价累计上涨30
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.